Does intravenous phenytoin cause pain or burning at the infusion site?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Intravenous Phenytoin Cause Pain?

Yes, intravenous phenytoin commonly causes pain and burning at the infusion site, along with potentially severe local tissue complications including the "purple glove syndrome."

Local Infusion Site Reactions

IV phenytoin is well-documented to cause local pain and irritation. The FDA label explicitly warns that soft tissue irritation and inflammation occurs at the injection site with and without extravasation, and describes pain distal to the injection site as part of "purple glove syndrome" 1. The 2014 emergency medicine guidelines note that IV phenytoin has "more serious adverse effects than oral, including hypotension, bradyarrhythmias, cardiac arrest, and extravasation injuries" 2.

Mechanism and Severity

The pain is primarily caused by:

  • High pH of the solution (alkalinity)
  • Propylene glycol content required for solubility 3

The severity ranges from:

  • Mild burning pain (most common)
  • Soft tissue irritation varying from slight tenderness to extensive necrosis and sloughing
  • Purple glove syndrome with edema, discoloration, and pain
  • Rare but serious complications requiring fasciotomies, skin grafting, or even amputation 1

Clinical Evidence

A 1983 study of 200 emergency department patients found that 29 complications were burning pain at the IV site out of 72 total complications in 51 patients 4. A 1994 randomized controlled trial demonstrated that phenytoin was associated with significantly higher pain at the infusion site in all subjects and significant phlebitis in 8 of 12 subjects, with cording in 6 subjects 5.

Risk Mitigation Strategies

The FDA mandates specific administration techniques 1:

  • Administer directly into a large peripheral or central vein through a large-gauge catheter
  • Test IV catheter patency with sterile saline flush before administration
  • Follow each injection with a sterile saline flush to avoid local venous irritation from alkalinity
  • Maximum infusion rate of 50 mg/min
  • Avoid intramuscular administration (causes pain, necrosis, and abscess formation)

Fosphenytoin as Alternative

Fosphenytoin causes significantly less pain and burning compared to phenytoin 6, 5. The 2014 guidelines note that fosphenytoin has "fewer adverse events in head-to-head analysis between IV fosphenytoin and IV phenytoin load" 2. A 1994 study showed fosphenytoin resulted in only mild pain in 2 of 12 subjects versus significant pain in all phenytoin subjects 5. Clinical experience confirms fosphenytoin "causes less pain and burning at the infusion site and minimal consequences in case of IV infiltration" 6.

Important Caveat

Despite superior tolerability, a 2002 study of 279 doses found no significant difference in adverse event rates requiring infusion rate reduction (phenytoin 6.5% vs fosphenytoin 6.4%) in routine emergency department use, though this may reflect overall adverse events rather than specifically infusion site pain 7.

Bottom Line for Clinical Practice

Pain at the infusion site is an expected and common adverse effect of IV phenytoin. While proper technique can minimize risk, the inherent properties of the formulation make some degree of local irritation nearly unavoidable. When feasible and cost-effective, fosphenytoin represents a better-tolerated alternative for parenteral phenytoin administration.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.